Mortality Trends in Crohn's Disease and Ulcerative Colitis: A Population-based Study in Québec, Canada

Inflammatory Bowel Diseases

Volumn 22, Issue 2, 2016, Pages 416-423

  Bitton, Alain ^a,b   Vutcovici, Maria ^a   Sewitch, Maida ^a   Suissa, Samy ^a,b,c   Brassard, Paul ^b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

inflammatory bowel disease; mortality; SMR; trend

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CAUSE OF DEATH; CHILD; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DEATH CERTIFICATE; DIGESTIVE SYSTEM CANCER; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INFANT; INFECTION; LUNG CANCER; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NEOPLASM; NEWBORN; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SEX DIFFERENCE; STANDARDIZED MORTALITY RATIO; ULCERATIVE COLITIS; VERY ELDERLY; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; PROGNOSIS; QUEBEC; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CANADA; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; QUEBEC; YOUNG ADULT;

EID: 84955574837     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000608     Document Type: Article

References (54)

1. Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology. 2007;133:1779-1786.
2. Jess T, Loftus EV Jr, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut. 2006;55: 1248-1254.
3. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46:336-343.
4. Bernstein CN, Nugent Z, Targownik LE, et al. Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut. 2015;64:1403-1411.
5. Rezaie A, Quan H, Fedorak RN, et al. Development and validation of an administrative case definition for inflammatory bowel diseases. Can J Gastroenterol. 2012;26:711-717.
6. Bitton A, Vutcovici M, Patenaude V, et al. Epidemiology of inflammatory bowel disease in Quebec: recent trends. Inflamm Bowel Dis. 2014;20: 1770-1776.
7. Institut de la statistique du Québec. Décès et taux de mortalité, Québec, 1900-2013. Institut de la statistique Québec. Available from: http://www. stat.gouv.qc.ca/statistiques/population-demographie/deces-mortalite/301. htm. Accessed October 27, 2014.
8. Canavan C, Abrams KR, Hawthorne B, et al. Long-term prognosis in Crohn's disease: an epidemiological study of patients diagnosed more than 20 years ago in Cardiff. Aliment Pharmacol Ther. 2007;25:59-65.
9. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481-489.
10. Jussila A, Virta LJ, Pukkala E, et al. Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. J Crohns Colitis. 2014;8:1088-1096.
11. Wolters FL, Russel MG, Sijbrandij J, et al. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006;55:510-518.
12. Persson PG, Bernell O, Leijonmarck CE, et al. Survival and cause-specific mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology. 1996;110:1339-1345.
13. Hoie O, Schouten LJ, Wolters FL, et al. Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut. 2007;56:497-503.
14. Romberg-Camps M, Kuiper E, Schouten L, et al. Mortality in inflammatory bowel disease in the Netherlands 1991-2002: results of a population-based study: the IBD South-Limburg cohort. Inflamm Bowel Dis. 2010; 16:1397-1410.
15. Selinger CP, Andrews J, Dent OF, et al. Cause-specific mortality and 30-year relative survival of Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2013;19:1880-1888.
16. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431-440.
17. Manninen P, Karvonen AL, Huhtala H, et al. Mortality in ulcerative colitis and Crohn's disease. A population-based study in Finland. J Crohns Colitis. 2012;6:524-528.
18. Masala G, Bagnoli S, Ceroti M, et al. Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978-2001. Gut. 2004;53:1309-1313.
19. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11:43-48.
20. Goldacre MJ, Wotton CJ, Yeates D, et al. Cancer in patients with ulcer-ative colitis, Crohn's disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol. 2008;20:297-304.
21. Bewtra M, Kaiser LM, TenHave T, et al. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis. 2013;19:599-613.
22. Herrinton LJ, Liu L, Levin TR, et al. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012;143:382-389.
23. Viscido A, Bagnardi V, Sturniolo GC, et al. Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study. Dig Liver Dis. 2001;33:686-692.
24. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohns Colitis. 2013;7:107-112.
25. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205-210.
26. Ananthakrishnan AN, McGinley EL, Saeian K, et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17: 976-983.
27. Murthy SK, Steinhart AH, Tinmouth J, et al. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment Pharmacol Ther. 2012;36:1032-1039.
28. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103: 1443-1450.
29. Pant C, Anderson MP, Deshpande A, et al. Health care burden of Clos-tridium difficile infection in hospitalized children with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1080-1085.
30. Ricciardi R, Ogilvie JW Jr, Roberts PL, et al. Epidemiology of Clostrid-ium difficile colitis in hospitalized patients with inflammatory bowel diseases. Dis Colon Rectum. 2009;52:40-45.
31. Sonnenberg A. Similar geographic variations of mortality and hospitali-zation associated with IBD and Clostridium difficile colitis. Inflamm Bowel Dis. 2010;16:487-493.
32. Ording AG, Horvath-Puho E, Erichsen R, et al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn's disease: a nationwide population-based cohort study. Inflamm Bowel Dis. 2013; 19:800-805.
33. Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenter-ol. 2012;107:1879-1887.
34. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol. 2012;107:579-588.
35. Ramadas AV, Gunesh S, Thomas GAO, et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59: 1200-1206.
36. Fedorak RN. Canadian association of gastroenterology clinical practice guidelines: the use of infliximab in Crohn's disease. Can J Gastroenterol. 2001;15:367-370.
37. Panaccione R, Fedorak RN, Aumais G, et al. Canadian association of gastroenterology clinical practice guidelines: the use of infliximab in Crohn's disease. Can J Gastroenterol. 2004;18:503-508.
38. Sadowski DC, Bernstein CN, Bitton A, et al. Canadian association of gastroenterology clinical practice guidelines: the use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol. 2009;23:185-202.
39. Feagan BG, Lemann M, Befrits R, et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis. 2012;18:152-160.
40. Leombruno JP, Nguyen GC, Grootendorst P, et al. Hospitalization and surgical rates in patients with Crohn's disease treated with in-fliximab: a matched analysis. Pharmacoepidemiol Drug Saf. 2011;20: 838-848.
41. Reich KM, Chang HJ, Rezaie A, et al. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther. 2014;40: 629-638.
42. Eaden JA, Mayberry JF. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut. 2002;51(suppl 5):V10-V12.
43. Itzkowitz SH, Present DH. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314-321.
44. Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colo-rectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561-1567; quiz 818-9.
45. Nguyen GC, Nugent Z, Shaw S, et al. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology. 2011;141:90-97.
46. Nguyen GC, Saibil F, Steinhart AH, et al. Postoperative health-care utilization in Crohn's disease: the impact of specialist care. Am J Gastro-enterol. 2012;107:1522-1529.
47. Murthy SK, Steinhart AH, Tinmouth J, et al. Impact of gastroenterologist care on health outcomes of hospitalised ulcerative colitis patients. Gut. 2012;61:1410-1416.
48. Ekbom A, Brandt L, Granath F, et al. Increased risk of both ulcerative colitis and Crohn's disease in a population suffering from COPD. Lung. 2008;186:167-172.
49. Raj AA, Birring SS, Green R, et al. Prevalence of inflammatory bowel disease in patients with airways disease. Respir Med. 2008;102:780-785.
50. Virta LJ, Ashorn M, Kolho KL. Cow's milk allergy, asthma, and pediatric IBD. J Pediatr Gastroenterol Nutr. 2013;56:649-651.
51. Brassard P, Vutcovici M, Ernst P, et al. Increased incidence of inflammatory bowel disease in Quebec residents with airway diseases. Eur Respir J. 2015;45:962-968.
52. Birrenbach T, Böcker U. Inflammatory bowel disease and smoking. A review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis. 2004;10:848-859.
53. Lee PN, Forey BA, Coombs KJ. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer. 2012;12:385.
54. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med. 2011;11:36.